(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 July 2020 (02.07.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/136441 A1

(51) International Patent Classification:
A61K 31/196 (2006.01) *A61K 47/20* (2006.01)
A61K 9/00 (2006.01) *A61K 47/36* (2006.01)
A61K 47/26 (2006.01) *A61K 47/42* (2006.01)
A61K 47/38 (2006.01) *A61P 25/28* (2006.01)
A61K 47/12 (2006.01)

(21) International Application Number:
PCT/IB2019/001409

(22) International Filing Date:
26 December 2019 (26.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/785,903 28 December 2018 (28.12.2018) US

(71) Applicant: **GNT PHARMA CO., LTD.** [KR/KR]; 1855-23 Yonggudae-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17096 (KR).

(72) Inventors: **LEE, Jinhwan**; 15, Dunjeon-ro, Pogok-eup, Cheoin-gu, Yongin-si 168NN-172NN (KR). **MOON, Jae Bong**; 20, Yatap-ro, Bundang-gu, Seongnam-si 131NN-137NN (KR). **GWAG, Byoung Joo**; 30-11, Heungduck 4-ro, Giheung-gu, Yongin-si 168NN-172NN (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS

(57) Abstract: The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

WO 2020/136441 A1

Compositions and Methods for Treating Neurodegenerative Disorders

RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application serial number 62/785,903, filed December 28, 2018, hereby incorporated by reference in its entirety.

FIELD OF THE DISCLOSURE

[0002] The present disclosure relates to pharmaceutical compositions for treating cognitive disorder in aging companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient suitable for oral administration. The present disclosure relates to methods for treatment of cognitive decline including canine CDS, dysthymia, involutive depression, and confusional syndrome.

BACKGROUND

[0003] The number of companion animals worldwide is steadily increasing. The number of household dogs and cats in top 20 countries is estimated to be approximately 256 million and approximately 236 million, respectively. Household dogs and cats live much longer these days, due to improvement in nutrition, disease treatment, and outstanding veterinary and pet-owner care. Therefore, there is growing interest in the treatment of age-related diseases in companion animals.

[0004] A number of aged or aging dogs and cats suffer from cognitive impairment that results from nervous system disorders including CDS, dysthymia, involutive depression, and confusional syndrome. Cognitive impairment is defined as trouble in remembering, learning new things, concentrating, or making decisions that can affect daily life. CDS is an age-related degenerative brain disease in dogs and cats. The prevalence of CDS has been reported to range from 14% to 60% in dogs over 8 years old [1-4]. Other reports show that 62% of companion dogs at 11-16 years old suffer from CDS, with the prevalence increasing markedly with age [5]. Therefore, a large number of dogs are afflicted with CDS, which can worsen

human-animal bond, lower the quality of life in animals, and consequently shorten the life span of the animals [6-8].

[0005] Pathophysiological changes seen in canine CDS include cerebrocortical and basal ganglia atrophy; increase in ventricle size; demyelination; an increase in the size and number of glial cells; neuronal loss especially in the cortical regions over the hippocampus; axonal degeneration; an accumulation of beta-amyloid plaques [6, 9, 10]. Cats with CDS are also accompanied by decreased number of neurons, beta amyloid deposition, and increased glial cells similar to canine CDS. In contrast to Alzheimer's disease (AD) in humans, neurofibrillary tangles widespread in AD have not been identified in the brains of dogs and cats with CDS, suggesting that CDS in dogs and cats is distinguishable from AD [11].

[0006] Dogs and cats diagnosed with CDS exhibit progressive impairment in cognitive and neurological functions. They show various behavioral problems such as getting lost in house, showing less daytime activity, no longer greeting to their families or other familiar animals, no reaction when called by name, going around in a circle or urination in unusual region [10, 12-15].

[0007] Although the rapidly growing population of dogs and cats with CDS is recently observed, CDS remains an unmet medical need. Selegiline, a selective irreversible inhibitor of monoamine oxidase B (MAO-B), is the only pharmaceutical medication that is approved by FDA for treating CDS [16]. Previous reports showed that selegiline enhanced cognitive function and improved behavioral function. However, recent data indicate that its beneficial effects are not maintained for a long time, indicating that selegiline therapy is just a symptomatological treatment. For example, the cognitive function in CDS dogs were improved within the first 2 weeks after selegiline treatment, but the beneficial effect in most of the dogs disappeared at 8 weeks after treatment [17-19]. Moreover, a large clinical trial involving 474 dogs with CDS over the age of 8 years old concluded that selegiline treatment should be administered at early onset of clinical signs [19].

[0008] A number of non-pharmacological therapies have been commercially available including dietary supplementation with antioxidants, L-carnitine, and omega-3 fatty acids that is just to improve the welfare of the dog by relieving the anxiety and supporting cognitive function. For optimal results, such dietary supplement should begin at the early stage of canine CDS. As there is no cure for CDS in canine and feline, disease-modifying compounds

and methods that can halt or slow down the progression of CDS need to be developed.

[0009] Over 400 clinical trials for the treatment of AD were conducted between 2002 and 2012, but memantine, a low to moderate affinity N-methyl-D-aspartate receptor antagonist, was the only drug approved for symptomatic treatment of AD based upon findings that it showed a small improvement in mental function and ability to perform daily activities in moderate-to-severe AD. Since then, large phase III clinical trials of drugs targeting beta amyloid, inflammation, or oxidative stress have been conducted for AD but all failed in showing beneficial effects, making the situation worse. However, nearly all the failed drugs reduced amyloid plaque burden and improved cognitive function in the two standard mouse models of AD, Tg2576 and APP/PS1 that overexpress familial AD mutations of genes, mutant amyloid precursor protein (APP), or APP and presenilin, respectively. Thus, pharmacological efficacy of drug candidates proven in preclinical animal models of AD is not translated for the treatment of AD in humans.

DETAILED DESCRIPTION

[0010] A 5-benzylaminosalicylic acid compound, or a pharmaceutically acceptable salt thereof, has been used for the treatment of AD and neurodegenerative diseases (US. Pat. No. 6,964,982). In a previous study, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid is verified as a potent spin-trapping molecule and microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitor effective at nanomolar concentrations, which results in not only blockade of neuronal death, axonopathy, and autophagosome formation but also increases of motor function activity and life span in a mouse model of amyotrophic lateral sclerosis [20].

[0011] A 5-benzylaminosalicylic acid compound, or a pharmaceutically acceptable salt thereof, was explored for the treatment of CDS in companion animals. Surprisingly, oral administration of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid for longer than 4 weeks markedly improved cognitive and neurobehavioral functions in aged companion dogs suffering from severe CDS. Moreover, the beneficial effects of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid were maintained for at least 4 weeks after the last administration. It was thus suggested that 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid could be a potential therapeutic option for treating CDS

through inhibiting both oxidative stress and inflammation. In some embodiments, the present disclosure is directed to compositions and methods comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment for cognitive and/or neurobehavioral impairment, e.g., in a neurological disease, in a companion animal.

Technical Problem

[0012] Accordingly, the present disclosure provides pharmaceutical compositions and methods useful for treating cognitive and/or neurobehavioral impairment, e.g., in a neurological disease, such as CDS, dysthymia, involutive depression, and confusional syndrome, in a companion animal.

Technical Solution

[0013] The present disclosure provides a compound of formula (I) for treating cognitive and/or neurobehavioral impairment, e.g., in a neurological disease, in a companion animal:



wherein,

X is selected from CO, SO_2 and $(CH_2)_n$;

R_1 is selected from hydrogen, C_1-C_6 alkyl and C_1-C_6 alkanoyl;

R_2 is selected from hydrogen and C_1-C_6 alkyl;

R_3 is selected from hydrogen and a C_1-C_5 acetyl group; and

R_4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group, which is unsubstituted or substituted with one or more substituents each independently selected from nitro, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_5 alkoxy, and C_1-C_5 haloalkoxy;

n is an integer from 1 to 5, inclusive;

or a pharmaceutically acceptable salt thereof.

[0014] The present disclosure provides methods of treating cognitive and/or neurobehavioral impairment, e.g., in neurological diseases, comprising administering to a companion animal in need thereof a compound of formula (I):



wherein,

X is selected from CO, SO_2 and $(CH_2)_n$;

R_1 is selected from hydrogen, C_1-C_6 alkyl and C_1-C_6 alkanoyl;

R_2 is selected from hydrogen and C_1-C_6 alkyl;

R_3 is selected from hydrogen and a C_1-C_5 acetyl group; and

R_4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group, which is unsubstituted or substituted with one or more substituents each independently selected from nitro, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_5 alkoxy, and C_1-C_5 haloalkoxy;

n is an integer from 1 to 5, inclusive;

or a pharmaceutically acceptable salt thereof.

[0015] In some embodiments, a number of compounds of formula (I) have been prepared and evaluated. In some embodiments, the compositions and methods comprise a 5-benzylaminosalicylic acid compound of formula (I) or its pharmaceutically acceptable salt.

[0016] In some embodiments, the 5-benzylaminosalicylic acid compound is 5-benzylaminosalicylic acid itself.

[0017] Preferable examples of 5-benzylaminosalicylic acid compounds include, but are not limited to, 2-hydroxy-5-phenethylamino-benzoic acid (Compound 1), 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (Compound 2), 2-hydroxy-5-[2-(3-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (Compound 3), 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 4), 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid (Compound 5), 5-[2-(4-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 6), 5-[2-(3,4-difluoro-phenyl)-

ethylamino]-2-hydroxy-benzoic acid (Compound 7), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 8), 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 9), 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 10), 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoic acid (Compound 11), 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid (Compound 12), 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid (Compound 13), 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid (Compound 14), 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid (Compound 15), 5-[3-(3,4-dichloro-phenyl)-propylamino]-2-hydroxy-benzoic acid (Compound 16), 2-hydroxy-5-(3-p-tolyl-propylamino)-benzoic acid (Compound 17), 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (Compound 18), 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (Compound 19), 5-benzylaminosalicylic acid (Compound 20), 5-(4-nitrobenzyl)aminosalicylic acid (Compound 21), 5-(4-chlorobenzyl)aminosalicylic acid (Compound 22), 5-(4-trifluoromethylbenzyl)aminosalicylic acid (Compound 23), 5-(4-fluorobenzyl)aminosalicylic acid (Compound 24), 5-(4-methoxybenzyl)aminosalicylic acid (Compound 25), 5-(2,3,4,5,6-pentafluorobenzyl)aminosalicylic acid (Compound 26), 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate (Compound 27), 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate (Compound 28), 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate (Compound 29), 5-(4-nitrobenzoyl)aminosalicylic acid (Compound 30), 5-(4-nitrobenzenesulfonyl)aminosalicylic acid (Compound 31), 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid (Compound 32), and 5-[3-(4-nitro-phenyl)-n-propyl]aminosalicylic acid (Compound 33). In certain preferred embodiments, the compound of formula (I) is Compound 2, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of formula (I) has the structure



[0018] The 5-benzylaminosalicylic acid compound or its pharmaceutically acceptable salt

of the present disclosure can be prepared by, but is not limited to, the reaction schemes represented in US. Pat. No. 6,573,402.

[0019] In some embodiments, the cognitive and/or neurobehavioral impairment is CDS, dysthymia, involutive depression, or confusional syndrome. In some embodiments, the compounds of formula (I) treat cognitive and/or neurobehavioral impairment in a companion animal. In some embodiments, the cognitive and/or neurobehavioral impairment is CDS.

[0020] In some embodiments, the treatment of cognitive and/or neurobehavioral impairment is through concurrent pharmacological inhibition of oxidative stress and inflammation. In some embodiments, the treatment of cognitive and/or neurobehavioral impairment is through inhibiting oxidative stress and prostaglandin E_2 synthesis. In some embodiments, the treatment of cognitive and/or neurobehavioral impairment is through inhibiting oxidative stress and microsomal prostaglandin E synthase-1.

[0021] In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from appetite, drinking behavior, vocalization, elimination behavior, sleeping pattern, aimless behavior, adaptive capabilities, social behavior, perceptual ability, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from vocalization, elimination behavior, sleeping pattern, aimless behavior, social behavior, perceptual ability, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from sleeping pattern, social behavior, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving changes in memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from orientation (e.g., staring blankly and getting lost in the home), memory (e.g., lack of recognition of owners and house-soiling), apathy (e.g., reduced time spent active and avoiding contact with owners), impaired olfaction (e.g., difficulty finding food), and locomotion.

[0022] In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from spatial orientation, social interaction, sleep–wake cycle, and house soiling.

[0023] In some embodiments, the companion animal exhibits pathophysiological changes. In some embodiments, the pathophysiological changes are selected from cerebrocortical

atrophy; basal ganglia atrophy; increase in ventricle size; demyelination; an increase in the size of glial cells; an increase in the number of glial cells; neuronal loss especially in the cortical regions over the hippocampus; axonal degeneration; and an accumulation of beta-amyloid plaques. In some embodiments, the pathophysiological changes are selected from an increase in the size of glial cells; an increase in the number of glial cells; neuronal loss; and an increase in beta-amyloid deposition.

[0024] In some embodiments, the companion animal is selected from a cat, a chinchilla, a dog, a ferret, a gerbil, a guinea pig, a hamster, a hedgehog, a mouse, a rabbit, and a rat. In certain preferred embodiments, the companion animal is a cat or a dog. In some embodiments, the companion animal is a canine or a feline.

[0025] *Definitions*

[0026] The definitions for the terms described below are applicable to the use of the term by itself or in combination with another term.

[0027] The term "acetoxy" refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0028] The term "acetyl" refers to a group represented by the general formula $CH_3C(O)$-.

[0029] An "alkyl" group (including 'alkyl' of haloalkyl) or "alkane" is a straight chained or branched non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 unless otherwise defined. A C_1-C_6 straight chained or branched alkyl group is also referred to as a "lower alkyl" group. In some embodiments, the alkyl is C_1-C_5 alkyl, and more preferably C_1-C_3 alkyl. More specifically, preferable alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl.

[0030] Moreover, the term "alkyl" (or "lower alkyl") as used throughout the specification, examples, and claims is intended to include both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents, if not otherwise specified, can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl such as an alkylC(O)), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a silyl

ether, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthiols, carbonyls (including ketones, aldehydes, carboxylates, and esters), $-CF_3$, -CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, $-CF_3$, -CN, and the like.

[0031] The term "C_{x-y}" when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. For example, the term "C_{x-y}alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-tirfluoroethyl, etc. C_0 alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. The terms "C_{2-y}alkenyl" and "C_{2-y}alkynyl" refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

[0032] The term "alkanoyl" refers to a group represented by the general formula hydrocarbyl-C(O)-, preferably alkyl-C(O)-.

[0033] The term "alkoxy" (including 'alkoxy' of haloalkoxy) refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto. In some embodiments, preferably, the alkoxy is C_1-C_5 alkoxy, and more preferably C_1-C_3 alkoxy. More specifically, preferable alkoxy includes, but is not limited to, methoxy, ethoxy, and propanoxy. Halogen includes, but is not limited to, fluoride, chloride, bromide, and iodide. Preferably, alkanoyl is C_2-C_{10} alkanoyl, and more preferably C_3-C_5 alkanoyl. More specifically, preferable alkanoyl includes, but is not limited to, ethanoyl, propanoyl, and cyclohexanecarbonyl.

[0034] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by



wherein each R^{10} independently represents a hydrogen or a hydrocarbyl group, or two R^{10} are taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0035] The term "aryl" as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 10-membered ring, more preferably a 6- to 10-membered ring or a 6-membered ring. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like. Exemplary substitution on an aryl group can include, for example, a halogen, a haloalkyl such as trifluoromethyl, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl such as an alkylC(O)), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a silyl ether, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety

[0036] The terms "halo" and "halogen" as used herein means halogen and includes chloro, fluoro, bromo, and iodo.

[0037] The term "lower" when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer non-hydrogen atoms in the substituent, preferably six or fewer. A "lower alkyl", for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms

within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).

[0038] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a haloalkyl, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that substituents can themselves be substituted, if appropriate. Unless specifically stated as "unsubstituted," references to chemical moieties herein are understood to include substituted variants. For example, reference to an "aryl" group or moiety implicitly includes both substituted and unsubstituted variants.

[0039] The term "pharmaceutically acceptable salt" of the present disclosure means salts produced by non-toxic or little toxic acid or base. In case that the compound of the present disclosure is acidic, base addition salts of the compound of the present disclosure can be made by reacting the free base of the compound with enough amount of desirable base and adequate inert solvent. Pharmaceutically acceptable base addition salt includes, but is not limited to, sodium, potassium, calcium, ammonium, magnesium or salt made by organic amino. In case that the compound of the present disclosure is basic, acid addition salts of the compound of

the compound can be made by reacting the free base of the compound with enough amount of desirable acid and adequate inert solvent. Pharmaceutically acceptable acid addition salt includes, but is not limited to, propionic acid, isobutylic acid, oxalic acid, malic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, hydrochloric acid, bromic acid, nitric acid, carbonic acid, monohydrogen-carbonic acid, phosphoric acid, monohydrogen-phosphoric acid, dihydrogen-phosphoric acid, sulfuric acid, monohydrogen-sulfuric acid, hydrogen iodide, and phosphorous acid. In addition, the pharmaceutically acceptable salt of the present disclosure includes, but is not limited to, a salt of amino acid like arginate and an analog of organic acid like glucuronic or galactunoric.

[0040] For example, a pharmaceutically acceptable salt of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (Compound 2), one preferable example of the present disclosure, can be prepared by the below reaction scheme 1. However, the following reaction methods are offered by way of illustration and are not intended to limit the scope of the disclosure.

<Reaction scheme 1>



[0041] In Scheme 1, M is a pharmaceutically acceptable metal or basic organic compound such as diethylamine, lithium, sodium and potassium.

[0042] In more detail, diethylamine salt can be prepared by dissolving a compound in alcohol, adding dropwise diethylamine, stirring the mixture, distilling in vacuo, and crystallizing the residue by adding ether. Alkali metal salt can be made by preparing desirable salt with inorganic reagent like lithium hydroxide, sodium hydroxide, potassium hydroxide in solvent like alcohol, acetone, acetonitrile and then freeze-drying. In addition, according to the similar method, lithium salt can be made with lithium acetate, sodium salt can be made

with sodium 2-ethylhexanoate or sodium acetate, and potassium salt can be made with potassium acetate.

[0043] Some of the compounds of the present disclosure may be hydrated form and may exist as solvated or unsolvated form. A part of compounds according to the present disclosure exist as crystal form or amorphous form, and any physical form is included in the scope of the present disclosure. In addition, some compounds of the present disclosure may contain one or more asymmetric carbon atoms or double bond, and therefore exists in two or more stereoisomeric forms like racemate, enantiomer, diastereomer, geometric isomer, etc. The present disclosure includes these individual stereoisomers of the compounds.

Compositions

[0044] The present disclosure also provides a composition comprising the 5-benzylaminosalicylic acid derivative represented by the above chemical formula (I) or its pharmaceutically acceptable salt; and pharmaceutically acceptable excipient or additive. The 5-benzylaminosalicylic acid derivative represented by the above chemical formula (I) or its pharmaceutically acceptable salt of the present disclosure may be administered alone. In some embodiments, the composition comprising a compound of formula (I) is administered with any convenient carrier, diluent, etc.

[0045] In some embodiments, the composition comprises from about 1 mg to about 1,000 mg of the compound of formula (I). In some embodiments, the composition comprises from about 10 mg to about 1,000 mg of the compound of formula (I). In some embodiments, the composition comprises from about 1 mg to about 500 mg of the compound of formula (I). In some embodiments, the composition comprises from about 1 mg to about 100 mg of the compound of formula (I). In some embodiments, the composition comprises from about 2 mg to about 50 mg of the compound of formula (I).

[0046] In some embodiments, a formulation for administration may be single-dose unit or multiple-dose unit. In some embodiments, the composition comprises a single dose unit. In some embodiments, the composition comprises a multiple-dose unit.

[0047] The composition for oral administration of the present disclosure may be formulated in a solid or liquid form. The solid formulation includes, but is not limited to, a powder, a granule, a tablet, a capsule, a suppository, etc. Also, the solid formulation may further include,

but is not limited to, a diluent, a flavoring agent, a binder, a preservative, a disintegrating agent, a lubricant, a filler, a plasticizer, etc. The liquid formulation includes, but is not limited to, a solution such as water solution and propylene glycol solution, a suspension, an emulsion, etc., and may be prepared by adding suitable additives such as a coloring agent, a flavoring agent, a stabilizer, a thickener, etc. In some embodiments, the composition is administered in a form selected from a capsule, a tablet, a powder, and a solution. In some embodiments, the composition is administered by mixing with a dietary supplement. In some embodiments, the composition is administered as a dietary supplement. In some embodiments, the composition is administered by mixing with food. In some embodiments, the composition is administered as a food composition. In some embodiments, the composition is administered by dissolving in water. In some embodiments, the composition is administered as a capsule with water. In some embodiments, the composition is administered as a chewable tablet.

[0048] For example, a powder can be made by simply mixing the 5-benzylaminosalicylic acid derivative of the present disclosure and pharmaceutically acceptable excipients like lactose, starch, microcrystalline cellulose. A granule can be prepared as follows: mixing the compound, a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient comprises a diluent and/or a pharmaceutically acceptable binder. In some embodiments, the binder is polyvinylpyrrolidone, hydroxypropylcellulose, etc.

[0049] In some embodiments, the composition is formed by wet-granulating with adequate solvent like water, ethanol, isopropanol, etc. In some embodiments, the composition is formed by direct-compressing with compressing power. In addition, a tablet can be made by mixing the granule with a pharmaceutically acceptable lubricant such as magnesium stearate and tableting the mixture.

[0050] The pharmaceutical composition of the present disclosure may be administered in forms of, but not limited to, oral formulation, injectable formulation (for example, intramuscular, intraperitoneal, intravenous, infusion, subcutaneous, implant), inhalable, intranasal, vaginal, rectal, sublingual, transdermal, topical, etc. depending on the disorders to be treated and the animal's conditions. The composition of the present disclosure may be formulated in a suitable dosage unit comprising a pharmaceutically acceptable and non-toxic carrier, additive and/ or vehicle, which all are generally used in the art, depending on the

routes to be administered. Depot type of formulation being able to continuously release drug for desirable time also is included in the scope of the present disclosure.

[0051] In some embodiments, the composition is a capsule comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 50% w/w to about 70% w/w lactose monohydrate;

about 2% w/w to about 8% w/w croscarmellose sodium;

about 0.1% w/w to about 1% w/w magnesium stearate; and

about 0.1% w/w to about 2% w/w sodium lauryl sulfate.

[0052] In some embodiments, the composition is a capsule comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 60% w/w lactose monohydrate;

about 5% w/w croscarmellose sodium;

about 0.5% w/w magnesium stearate; and

about 1% w/w sodium lauryl sulfate.

[0053] In some embodiments, the composition is a food composition comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 30% w/w to about 50% w/w starch;

about 15% w/w to about 25% w/w crude protein;

about 10% w/w to about 20% crude fat;

about 0.1% w/w to about 5% w/w crude fiber;

about 1% w/w to about 10% w/w crude ash;

about 0.1% w/w to about 5% w/w arginine;

about 0.1% w/w to about 2.5% w/w calcium;

about 0.1% w/w to about 3% w/w lysine;

about 0.1% w/w to about 3% w/w methionine plus cystine; and

about 0.1% w/w to about 2.5% w/w phosphorus.

[0054] In some embodiments, the composition is a food composition comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 42.7% w/w starch;

about 21.0% w/w crude protein;

about 14% w/w crude fat;

about 1.9% w/w crude fiber;

about 6.1% w/w crude ash;

about 1.4% w/w arginine;

about 0.75% w/w calcium;

about 1.1% w/w lysine;

about 1.18% w/w methionine plus cystine; and

about 0.5% w/w phosphorus.

[0055] In some embodiments, the composition is a dietary supplement comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 5% w/w to about 20% w/w crude protein;

about 0.1% w/w to about 5% w/w crude fat;

about 0.1% w/w to about 5% w/w crude fiber;

about 0.1% w/w to about 5% w/w crude ash;

about 0% w/w to about 1% w/w calcium;

about 0% w/w to about 2% w/w potassium; and

about 60% w/w to about 95% w/w water.

[0056] In some embodiments, the composition is a dietary supplement comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 12.0% w/w crude protein;

about 1.5% w/w crude fat;

about 0.4% w/w crude fiber;

about 1.5% w/w crude ash;

about 0.02% w/w calcium;

about 0.1% w/w potassium; and

about 78.0% w/w water.

[0057] In some embodiments, the composition is a chewable tablet comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 0.1% w/w to about 5% w/w silicon dioxide;

about 0% w/w to about 2% w/w benzoic acid;

about 0% w/w to about 1% w/w sorbic acid;

about 0.1% w/w to about 10% w/w magnesium stearate;

about 10% w/w to about 30% w/w cellulose;

about 30% w/w to about 50% w/w chicken source;

about 0.1% w/w to about 5% w/w dry yeast; and

about 10% w/w to about 30% w/w glucose.

[0058] In some embodiments, the composition is a chewable tablet comprising:

about 1 mg to about 1000 mg of the compound of formula (I);

about 3% w/w silicon dioxide;

about 0.05% w/w benzoic acid;

about 0.01% w/w sorbic acid;

about 5% w/w magnesium stearate;

about 20% w/w cellulose;

about 40% w/w chicken powder;

about 3% w/w dry yeast; and

about 19% w/w glucose.

[0059] The present disclosure also provides a use of the 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt for treatment of cognitive decline in animals. That is, the present disclosure provides a pharmaceutical composition for treatment of cognitive decline in animals, comprising the 5-benzylaminosalicylic acid derivative represented by the above chemical formula (I) or its pharmaceutically acceptable salt. More specifically, the 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt can be used for treatment of cognitive decline in animals including cognitive dysfunction syndrome (e.g., canine cognitive dysfunction syndrome), dysthymia, involutive depression, and confusional syndrome. In some embodiments, the cognitive decline is caused by CDS.

[0060] In some embodiments, the compositions are used in the manufacture of a medicament for the treatment of cognitive dysfunction syndrome (CDS) in a companion animal. In some embodiments, the compositions are used in the manufacture of a medicament for treating CDS through concurrent pharmacological inhibition of oxidative stress and inflammation. In some embodiments, the compositions are used in the manufacture of a medicament for treating CDS through inhibiting oxidative stress and prostaglandin E_2 synthesis. In some embodiments, the compositions are used in the manufacture of a medicament for treating CDS through inhibiting oxidative stress and microsomal

prostaglandin E synthase-1. However, the use of the 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt according to the present disclosure is not limited to the above concrete disease names.

[0061] The disclosure provides for use of the 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt to prepare a pharmaceutical product for treating cognitive and/or neurobehavioral impairment, such as reducing or slowing down a decline of social interaction, reducing age-related behavioral changes, increasing of ability in training, improving attention, keeping healthy of brain function, reducing memory loss, and treating cognitive decline in a companion animal, such as a canine or a feline. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from appetite, drinking behavior, vocalization, elimination behavior, sleeping pattern, aimless behavior, adaptive capabilities, social behavior, perceptual ability, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from vocalization, elimination behavior, sleeping pattern, aimless behavior, social behavior, perceptual ability, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from sleeping pattern, social behavior, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms involving changes in memory. In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from orientation (e.g., staring blankly and getting lost in the home), memory (e.g., lack of recognition of owners and house-soiling), apathy (e.g., reduced time spent active and avoiding contact with owners), impaired olfaction (e.g., difficulty finding food), and locomotion.

[0062] In some embodiments, the companion animal exhibits symptoms involving behavioral changes selected from spatial orientation, social interaction, sleep–wake cycle, and house soiling.

[0063] In some embodiments, the companion animal exhibits pathophysiological changes. In some embodiments, the pathophysiological changes are selected from cerebrocortical atrophy; basal ganglia atrophy; increase in ventricle size; demyelination; an increase in the size of glial cells; an increase in the number of glial cells; neuronal loss especially in the cortical regions over the hippocampus; axonal degeneration; and an accumulation of beta-

amyloid plaques. In some embodiments, the pathophysiological changes are selected from an increase in the size of glial cells; an increase in the number of glial cells; neuronal loss; and an increase in beta-amyloid deposition.

[0064] For treating cognitive decline in feline companion animal, the compound of the present disclosure may be administered daily at a dose of approximately 0.01 mg/kg to approximately 200 mg/kg, preferably approximately 0.1 mg/kg to approximately 30 mg/kg. In some embodiments, the compound of formula (I) is administered in a dose from about 0.1 mg per kilogram of body weight to about 10 mg per kilogram of body weight. However, the dosage may be varied according to the animal's conditions (age, sex, body weight, etc.), the severity of disease in animals in need thereof, the used effective components, diets, etc. The compound of the present disclosure may be administered once a day or several times a day in divided doses, if necessary. In some embodiments, the compound of formula (I) is administered one, two, or three times daily. In some embodiments, the compound of formula (I) is administered once daily.

EXAMPLES

[0065] Compound 2, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid, was used as a representative compound. Hereinafter, the present disclosure is described in considerable detail to help those skilled in the art understand the present disclosure. However, the following examples are offered by way of illustration and are not intended to limit the scope of the disclosure. It is apparent that various changes may be made without departing from the spirit and scope of the disclosure or sacrificing all its material advantages.

1. Study design and subjects

[0066] In preliminary data, the maximally beneficial effects such as improvement in cognitive and motor functions were shown in animal models of AD (APP/PS1 mice) and amyotrophic lateral sclerosis (G93A mice) following oral administration of Compound 2 at the dose of 2.5 mg/kg.

[0067] Following the oral administration of Compound 2 at the dose of 2.5 mg/kg in mice, C_{max} (mean maximum plasma concentration) and AUC (area under the plasma level-time curve) were measured 5.19 ± 0.96 μg/mL and 9.61 ± 1.38 μg·hr/mL, respectively.

[0068] The systemic toxic potential of Compound 2 in beagle dogs was investigated in

Huntington Life Science, a large non-clinical contract research organization in Cambridgeshire, England. Three groups each comprising three males and three females, received Compound 2 at doses of 20, 65, or 200 mg/kg/day for 13 weeks. Daily oral administration of Compound 2 to beagle dogs caused adaptive changes in the liver and kidney and secondary finding in the thyroid. There was no evidence of toxicity, though treated animals tended to struggle at the time of dose administration. The principal treatment-related findings all showed at least partial recovery during the four-week recovery period, with most showing full recovery. Consequently, 200 mg/kg/day was considered the no-observed-adverse-effect level (NOAEL) in dogs.

[0069] In pharmacokinetic study, C_{max} and AUC in beagle dogs were 10.6 μg/mL and 75.1 μg·hr/mL, respectively, following oral administration of 20 mg/kg/day Compound 2. Based upon the safety and pharmacokinetic profile of Compound 2, a dose of 10 mg/kg/day was chosen to investigate safety and efficacy of Compound 2 in canine CDS.

[0070] In stability test, Compound 2 was stable at 25 ℃ for at least 60 months. Additionally, the capsule and chewable formulations of Compound 2 were stable at 25 ℃ for at least 24 and 12 months, respectively.

[0071] The companion animals tested in the study were 22 elderly dogs (12-19 years of age) diagnosed with CDS. The subjects of the examples are presented in Table 1. Each dog enrolled for the present study met the following criteria: body weight <12 kg (regardless of gender), dogs which had lived with the owner for at least 90 days, dogs which were able to take oral medicine, dogs with CDS diagnosed by investigator (canine cognitive dysfunction rating (CCDR) scale ≥ 50 points) and dogs with informed consent of their owners. Dogs with a pregnancy or lactating, with hypersensitivity against salicylic acid derivatives, or with the underlying disease (i.e. renal dysfunction, visual loss, heart failure, or renal failure) were excluded. In addition, dogs which had participated any other clinical trials within 90 days or dogs which had not only CDS but also other neurodegenerative diseases were excluded.

[0072] This study was a randomized, blind, placebo-controlled clinical trial to investigate the efficacy and safety of Compound 2 in dogs with CDS. To investigate the efficacy of Compound 2, two questionnaires were evaluated: CCDR scale and canine dementia scale (CADES). To measure the safety of Compound 2, not only the occurrence of adverse events was investigated but also the vital signs, physical examination, and blood tests were

performed in the dogs. Compound 2 was prescribed for oral administration of 10 mg/kg once-daily dosing for 8 weeks. Subjects 3 and 4 received Compound 2 additionally for 4 weeks with approval of the principal investigator. Instead of Compound 2, subjects 18-22 received placebo for 8 weeks. In this study, we allowed the dogs to be administered Compound 2 in various ways: mix with dietary supplement (subjects 1 and 3), mix with food (subjects 2 and 6), dissolve in water (subject 4), or capsule with water (subject 5), or chewable tablet with water (subjects 7-22).

Subject No.	Dog Name	Breed	Sex	Age	Wt (kgs)
1	Rich	Poodle	M	15	1.9
2	Sarang	Mix	F	18	6.7
3	Ggandol	Miniature Pinscher	M	15	4.6
4	Ddol	Yorkshire terrier	F	13	1.5
5	Wanggun	Shih Tzu	M	14	7.1
6	Taro	Mix	F	18	3.8
7	Donggun	Mixed	M	12	5.7
8	Sarang II	Schnauzer	F	16	5.0
9	Dream	Schnauzer	F	15	3.6
10	Goldstar	Maltese	F	15	2.4
11	Fullmoon	Schnauzer	F	15	5.2
12	Youngsik	Dachshund	M	19	5.1
13	Genie	Toy Poodle	F	15	2.8
14	Danvi	Schnauzer	F	14	10.5
15	Cherry	Poodle	M	15	3.5
16	Wangbok	Maltese	M	18	4.4
17	Jorong	Maltese	M	16	4.0
18	Sorong	Schnauzer	F	15	3.8
19	Wooju	Chihuahua	M	12	3.5
20	Luna	Yorkshire terrier	F	15	2.8

21	Choco	Cocker Spaniel	M	13	10.5
22	Ming	Yorkshire terrier	F	16	3.1

Table 1. Subjects of Examples

2. Questionnaires in dogs with CDS

[0073] Rating scales are essential tools for CDS diagnosis, staging, assessment, and careful monitoring of the disease symptoms as well as for evaluation of the efficacy of therapeutic strategies. Several rating scales have been developed during the last decade e.g. CCDR scale [21-24]. To assess the severity of CDS in this study, two questionnaires (CCDR scale and CADES) were performed before and after oral administration of Compound 2 by a veterinarian. Questionnaires include a broad range of items measuring appetite, drinking behavior, barking, elimination behavior, day/night sleeping pattern, aimless behavior, adaptive capabilities, social behavior, perceptual ability, disorientation, and memory.

2.1 The examination according to CCDR scale

[0074] CCDR scale consists of 13 items based on CDS symptoms (Table 2). The 13 kinds of behaviors included various problems related to orientation (staring blankly, getting lost in the home), memory (lack of recognition of owners, house-soiling), apathy (reduced time spent active, avoiding contact with owners), impaired olfaction (difficulty finding food), and locomotion. These problems compromise both the dog's quality of life and the dog-owner bond [25, 26]. Scores ≥50 on the CCDR are indicative of CDS in the aged dogs (12-19 years of age). In this study, we compared the CCDR scores before and after administration of Compound 2 in dogs with CDS.

	(1) Never	**(2) Once a month**	**(3) Once a week**	**(4) Once a day**	**(5) >once a day**	**Score**
How often does your dog pace up and down, walk in circles and/or wander with no direction or purpose?						
How often does your dog stare blankly at the walls or floor?						
How often does your dog get stuck behind objects						

and is unable to get around?						
How often does your dog fail to recognize familiar people or pets?						
How often does your dog walk into walls or doors?						
How often does your dog walk away while, or avoid, being patted?						
	Much less	**Slightly less**	**The same**	**Slightly more**	**Much more**	
Compared with 6 months ago, does your dog now pace up and down, walk in circles and/or wander with no direction or purpose						
Compared with 6 months ago, does your dog now stare blankly at the walls or floor						
Compared with 6 months ago, does your dog urinate or defecate in an area it has previously kept clean (if your dog has never house-soiled, tick 'the same')						
Compared with 6 months ago, does your dog have difficulty finding food dropped on the floor						x2
Compare with 6 months ago, does your dog fail to recognize familiar people or pets						x3
	Much more	**Slightly more**	**The same**	**Slightly less**	**Much less**	
Compared with 6 months ago, is the amount of time your dog spends active						

Table 2. Canine cognitive dysfunction rating (CCDR) scale

[0075] Although a total of 22 companion dogs with CDS were initiated in the study, 17 companion dogs received 8-week treatment with Compound 2, and subjects 1 and 2 underwent aging-dependent nephrotoxicity and natural death at 7 weeks after administration. Even four weeks after oral administration of Compound 2, most companion dogs with CDS showed the remarkably reduced tendencies for behaviors on the CCDR scale, indicating that dogs treated with Compound 2 showed near normal cognitive function within 4 weeks (Table 3). Also, the frequency of abnormal behaviors was decreased, and their social interaction was improved in most of the dogs. The improved CCDR score after administration of Compound 2 was observed up to 8 weeks.

Subjects No.	0 week	4 weeks		8 weeks	
	Score	score	change	score	change
1	69	53	-16	-	-
2	59	49	-10	-	-
3	74	30	-44	30	-44
4	62	49	-13	42	-20
5	60	38	-22	34	-26
6	51	40	-11	46	-5
7	64	55	-9	41	-23
8	67	56	-11	51	-16
9	65	53	-12	54	-11
10	67	55	-12	27	-40
11	74	56	-18	50	-24
12	59	54	-5	53	-6
13	61	60	-1	59	-2
14	63	52	-11	53	-10
15	59	50	-9	50	-9
16	50	43	-7	43	-7
17	69	63	-6	50	-19

Table 3. CCDR Scores of subjects following administration of Compound 2

[0076] To determine whether the beneficial effects of Compound 2 could be maintained after discontinuation of the drug treatment, follow-up studies were performed in 6 companion dogs. In subjects 3, 4, 7, 8, 10, and 11 that received 8- or 12-week treatment with Compound 2, the beneficial effects of Compound 2 were observed over the 4 or 8 weeks after the last administration of the drug (Tables 4 and 5). Importantly, the social interaction, appropriate elimination, and changes in the sleep-wake activity cycle were remarkably improved. This implies that Compound 2 can be applied to treat CDS by improving cognitive deficits and slowing down progression of the disease.

Discontinuation

↓

Subject No.	0 week	4 weeks	8 weeks	12 weeks	16 weeks	20 weeks
3	74	30	30	32	38	36
4	62	49	42	43	44	43

Table 4. CCDR Scores of subjects following administration and discontinuation of Compound 2

Discontinuation

↓

Subjects No.	0 week	4 weeks	8 weeks	12 weeks
7	64	55	41	50
8	67	56	51	54
10	67	55	27	48
11	74	56	50	48

Table 5. CCDR Scores of subjects following administration and discontinuation of Compound 2

2.2 The examination according to CADES

[0077] To ensure and confirm the CCDR scale, we used an additional questionnaire, CADES which contains 17 items distributed into four domains, related to changes in dogs' behaviors: spatial orientation, social interaction, sleep–wake cycle, and house soiling (Table 6) [3]. It can be classified according to various stages of cognitive impairment: mild, moderate, and severe cognitive impairment. It is known well that CADES is also suitable for long-term assessment of the progression of cognitive impairment in canine, and potentially as efficacy readout for treatments.

Domain/items	Score
A. Spatial orientation	
1. disorientation in a familiar environment (inside/outside)	
2. to recognize familiar people and animals inside or outside the house/apartment	
3. abnormally respond to familiar objects (a chair, a wastebasket)	
4. aimlessly wandering (motorically restless during day)	
5. a reduced ability to do previously learned task	
SCORE (0–25)	
B. Social interaction	
6. changes in interaction a man/dog, dog/other dog (playing, petting, welcoming)	
7. changes in individual behavior of dog (exploration behavior, play, performance)	
8. response to commands and ability to learn new task	
9. irritable	
10. expression of aggression	
SCORE (0–25)	
C. Sleep–wake cycles	
11. abnormally responds in night (wandering, vocalization, motorically restless)	
12. switch over from insomnia to hypersomnia	
SCORE x2 (0–20)	
D. House soiling	
13. eliminate at home at random locations	
14. eliminate in its kennel or sleeping area	
15. changes in signalization for elimination activity	
16. eliminate indoors after a recent walk outside	
17. eliminate at uncommon locations (grass, concrete)	
SCORE (0–25)	
Frequency: 0 points – abnormal behavior of the dog was never observed 2 points – abnormal behavior of the dog was detected at least once in the last 6 months 3 points – abnormal behavior appeared at least once per month 4 points – abnormal behavior was seen 2–4 times per month 5 points – abnormal behavior was observed several times a week.	
Total score (A + B + C + D) (0–95) Clinical stage: Normal aging (Score 0–7), Mild cognitive impairment (8–23), Moderate cognitive impairment (24–44), Severe cognitive impairment (45–95)	

Table 6. Canine dementia scale (CADES)

[0078] The scores on spatial orientation and variation were presented in Table 7. At 4 weeks after administration, 10 (59%) of 17 companion dogs showed improvement in their spatial disorientation. Subjects 3, 4, and 10 showed almost normal behavior in spatial orientation items. In 9 (60%) of 15 companion dogs, the beneficial effects were observed at 8 weeks after

oral administration of Compound 2. Overall, these results indicate that Compound 2 improves the spatial-oriented ability in dogs with CDS.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	change	score	change
1	24	21	-3	-	-
2	25	24	-1	-	-
3	24	5	-19	4	-20
4	14	5	-9	9	-5
5	23	20	-3	15	-8
6	19	18	-1	13	-6
7	18	16	-2	15	-3
8	18	17	-1	17	-1
9	22	24	2	25	3
10	16	5	-11	0	-16
11	24	24	0	24	0
12	20	20	0	20	0
13	25	25	0	22	-3
14	20	20	0	20	0
15	15	13	-2	13	-2
16	15	18	3	15	0
17	20	25	5	23	3

Table 7. CADES scores of spatial orientation (items 1-5) in subjects at 0, 4, and 8 weeks following administration of Compound 2

[0079] The social interaction scores in CADES are presented in the Table 8. After 4 weeks administration of Compound 2, social interaction in most participant dogs, except subjects 5, 8, 11, 12, 14, and 17 were markedly improved. Although 3 dogs (subjects 3, 4, and 10) had showed severe abnormal social behaviors before treatment with Compound 2, their social behavior was nearly similar to normal aged dogs at 4 weeks after treatment. In addition, most

dogs showed improved social activities at 8 weeks after Compound 2 treatment. More importantly, 8 (53%) of the 15 companion dogs at 8 weeks after administration of Compound 2 showed further improvement in the social interaction compared with improvement at 4 weeks after administration of Compound 2. Overall, these results indicate that Compound 2 improves the social interaction activity in dogs with CDS.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	change	score	change
1	20	19	-1	-	-
2	20	13	-7	-	-
3	16	5	-11	3	-13
4	15	5	-10	15	0
5	14	14	0	5	-9
6	18	17	-1	10	-8
7	19	17	-2	14	-5
8	13	13	0	11	-2
9	18	14	-4	19	1
10	14	0	-14	4	-10
11	25	25	0	24	-1
12	15	15	0	15	0
13	19	14	-5	16	-3
14	10	10	0	10	0
15	19	18	-1	18	-1
16	15	13	-2	9	-6
17	20	20	0	13	-7

Table 8. CADES scores of social interaction (items 6-10) in subjects at 0, 4, and 8 weeks following administration of Compound 2

[0080] The changes of sleep-wake cycle in CADES were quantified in Table 9. Before administration of Compound 2 all dogs except subject 14 had severe abnormal behaviors on

sleep-wake cycle (item 11), but 10 (67%) of 15 companion dogs were significantly improved at 8 weeks after administration of Compound 2. Meanwhile, switch over from insomnia to hypersomnia (item 12) had been observed in 14 (82%) of 17 companion dogs, but the abnormal changes almost disappeared after administration of Compound 2.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	Change	score	change
1	10	8	-2	-	-
2	16	10	-6	-	-
3	16	4	-12	0	-16
4	20	18	-2	10	-10
5	10	6	-4	0	-10
6	18	16	-2	14	-4
7	14	18	4	12	-2
8	18	16	-2	12	-6
9	20	20	0	20	0
10	18	0	-18	0	-18
11	18	18	0	16	-2
12	10	10	0	0	-10
13	20	20	0	20	0
14	8	8	0	8	0
15	20	18	-2	16	-4
16	10	14	4	12	2
17	20	20	0	6	-14

Table 9. CADES scores of sleep–wake cycles (items 11-12) in subjects at 0, 4, and 8 weeks following administration of Compound 2

[0081] The frequency of house soiling was shown in Table 10. After 8 weeks of administration of Compound 2, the house soiling behavior was decreased in all subjects

except subjects 4, 12, 13, and 17. Especially, subjects 3, 5, and 10 showed no soiling at 8 weeks after administration of Compound 2.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	Change	score	change
1	23	18	-5	-	-
2	5	4	-1	-	-
3	10	0	-10	0	-10
4	4	5	1	4	0
5	15	9	-6	0	-15
6	18	16	-2	8	-10
7	19	14	-5	12	-7
8	23	22	-1	18	-5
9	15	11	-4	14	-1
10	18	3	-15	0	-18
11	22	22	0	21	-1
12	19	19	0	20	1
13	5	5	0	5	0
14	21	19	-2	19	-2
15	20	17	-3	17	-3
16	10	10	0	4	-6
17	25	25	0	25	0

Table 10. CADES scores of house soiling (items 13-17) in subjects at 0, 4, and 8 weeks following administration of Compound 2

[0082] Total CADES score was shown in Table 11. The score revealed that the cognitive dysfunction behaviors in all companion dogs with CDS, except subject 9, were gradually decreased after administration of Compound 2. At 8 weeks after oral administration of Compound 2, the significant improvement in cognitive function was observed from severe to moderate, weak, or normal level.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	change	Score	change
1	77	66	-11	-	-
2	66	51	-15	-	-
3	66	14	-52	7	-59
4	53	33	-20	38	-15
5	62	49	-13	20	-42
6	73	67	-6	45	-28
7	70	65	-5	53	-17
8	72	68	-4	58	-14
9	75	69	-6	78	3
10	66	8	-58	4	-62
11	89	89	0	85	-4
12	64	64	0	55	-9
13	69	64	-5	63	-6
14	59	57	-2	57	-2
15	74	66	-8	64	-10
16	50	55	5	40	-10
17	85	90	5	67	-18

Table 11. Total CADES Scores of subjects at 0, 4, and 8 weeks following administration of Compound 2

[0083] The beneficial effects of Compound 2 in 6 companion dogs (subjects 3, 4, 7, 8, 10, and 11) were observed even over the next 4 or 8 weeks after the administration was discontinued (Tables 12 and 13). The sleep patterns, house soiling, social interaction, and behavioral activities were significantly improved after treatment with Compound 2. Also, the subjects became more obedient to their owners and showed reduced aggressiveness. These results imply that Compound 2 can be administered to reduce cognitive impairment and slow down disease progression in canine CDS.

Discontinuation

↓

Subjects No.	0 week	4 weeks	8 weeks	12 weeks	16 weeks	20 weeks
3	66	14	7	0	0	0
4	53	33	38	24	33	31

Table 12. Total CADES Scores of subjects following administration and discontinuation of Compound 2

Discontinuation

↓

Subjects No.	0 week	4 weeks	8 weeks	12 weeks
7	70	65	53	58
8	72	68	58	51
10	66	8	4	36
11	89	89	85	77

Table 13. Total CADES Scores of subjects following administration and discontinuation of Compound 2

2.3 Results of CCDR and CADES in dogs receiving placebo

[0084] To clarify the effects of Compound 2 on the cognitive impairment, 5 dogs (subjects 18-22) with CDS received placebo. CCDR and CADES scores in most dogs receiving placebo showed no significant changes or increases at 8 weeks after placebo treatment, indicating that placebo treatment did not affect the cognitive function. Overall, it is strongly implied that Compound 2 can be administered to reduce cognitive impairment in canine CDS.

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	change	Score	change

18	60	60	0	77	17
19	66	61	-5	63	-3
20	58	52	-6	52	-6
21	53	64	11	66	13
22	60	72	12	72	12

Table 14. CCDR Scores of subjects following administration of placebo

Subjects No.	0 week	4 weeks		8 weeks	
	score	score	change	Score	change
18	85	95	10	94	9
19	73	72	-1	82	9
20	58	52	-6	52	-6
21	45	56	11	58	13
22	79	70	-9	93	14

Table 15. Total CADES Scores of subjects following administration of placebo

3. Safety assessment in dogs with CDS

[0085] During this study, the safety of Compound 2 in dogs with CDS was evaluated at every visit. As a result, no significant changes in the blood toxicity test were observed, and treatment-related adverse events did not occurr as well.

4. Conclusion

[0086] Two questionnaires were used to evaluate the effects of Compound 2 on cognitive function in the companion dogs with CDS. In the CCDR scale, the administration of Compound 2 substantially improved cognitive function almost back to normal score. Consistent with CCDR scale, severe cognitive and neurobehavioral impairment in dogs with CDS was significantly alleviated within 8 weeks after administration of Compound 2. These beneficial effects were maintained over 4 or 8 weeks after 8- or 12-week administration of Compound 2 was completed. Also, no adverse events or toxicity were observed during the study. On the other hand, there was no significant improvement in placebo group. Taken

together, these findings strongly imply that Compound 2 can be applied to treat CDS in canines and also felines.

INDUSTRIAL APPLICABILITY

[0087] The present disclosure provides compositions comprising Compound 2 and methods administering a therapeutically effective amount of Compound 2 for treating cognitive and neurobehavioral impairment in neurological diseases including CDS, dysthymia, involutive depression, and confusional syndrome in canines or felines. The compositions and methods of the present disclosure are very useful for reducing or slowing down cognitive and neurobehavioral impairments in the age-related neurological diseases in canines or felines.

OTHER PUBLICATIONS

1. Azkona, G., et al., *Prevalence and risk factors of behavioural changes associated with age-related cognitive impairment in geriatric dogs.* J Small Anim Pract, 2009. **50**(2): p. 87-91.
2. Neilson, J.C., et al., *Prevalence of behavioral changes associated with age-related cognitive impairment in dogs.* J Am Vet Med Assoc, 2001. **218**(11): p. 1787-91.
3. Madari, A., et al., *Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES).* Appl Anim Behav Sci., 2015. **171**: p. 138-45.
4. Salvin, H.E., et al., *Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs.* The Veterinary Journal, 2010. **184**(3): p. 277-281.
5. Hart, B.L. and L.A. Hart, *Selecting, raising, and caring for dogs to avoid problem aggression.* Journal of the American Veterinary Medical Association, 1997. **210**(8): p. 1129.
6. Landsberg, G.M., J. Nichol, and J.A. Araujo, *Cognitive dysfunction syndrome: a disease of canine and feline brain aging.* Vet Clin North Am Small Anim Pract, 2012. **42**(4): p. 749-68, vii.
7. Landsberg, G.M., T. Deporter, and J.A. Araujo, *Clinical signs and management of anxiety, sleeplessness, and cognitive dysfunction in the senior pet.* Vet Clin North Am Small Anim Pract, 2011. **41**(3): p. 565-90.
8. Gonzalez-Martinez, A., et al., *Effect of age and severity of cognitive dysfunction on two simple tasks in pet dogs.* Vet J, 2013. **198**(1): p. 176-81.
9. Cummings, B.J., et al., *β-amyloid accumulation correlates with cognitive dysfunction in the aged canine.* Neurobiology of learning and memory, 1996. **66**(1): p. 11-23.
10. Cummings, B.J., et al., *β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.* Neurobiology of aging, 1996. **17**(6): p. 921-933.
11. Cummings, B.J., et al., *Diffuse plaques contain C-terminal Aβ42 and not Aβ40: evidence from cats and dogs.* Neurobiology of aging, 1996. **17**(4): p. 653-659.

12. Ozawa, M., et al., *The Relation between canine cognitive dysfunction and age-related brain lesions.* J Vet Med Sci, 2016. **78**(6): p. 997-1006.

13. Rofina, J., et al., *Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease.* Brain research, 2006. **1069**(1): p. 216-226.

14. Head, E., et al., *Visual-discrimination learning ability and β-amyloid accumulation in the dog.* Neurobiology of aging, 1998. **19**(5): p. 415-425.

15. Tapp, P.D., et al., *Frontal lobe volume, function, and β-amyloid pathology in a canine model of aging.* Journal of Neuroscience, 2004. **24**(38): p. 8205-8213.

16. Druce, K., *Canine cognitive dysfunction–recognition and treatment.* Veterinary Nursing Journal, 2014. **29**(8): p. 268-270.

17. Ruehl, W., et al., *Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy*, in *Progress in Brain Research*. 1995, Elsevier. p. 217-225.

18. Head, E., et al., *Spatial learning and memory as a function of age in the dog.* Behavioral neuroscience, 1995. **109**(5): p. 851.

19. Campbell, S., A. Trettien, and B. Kozan, *A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.* Vet Ther, 2001. **2**(1): p. 24-39.

20. Shin, J.H., et al., *Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis.* Journal of neurochemistry, 2012. **122**(5): p. 952-961.

21. Colle, M.A., et al., *Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior.* Neurobiol Aging, 2000. **21**(5): p. 695-704.

22. Pugliese, M., et al., *Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia.* Prog Neuropsychopharmacol Biol Psychiatry, 2005. **29**(4): p. 603-10.

23. Schneider, B.M. and M.H. Erhard, *[Canine cognitive dysfunction syndrome: prevalence, diagnosis and therapeutic measures].* Tierarztl Prax Ausg K Kleintiere Heimtiere, 2010. **38**(2): p. 113-8.

24. Salvin, H.E., et al., *The canine cognitive dysfunction rating scale (CCDR): a data-driven and ecologically relevant assessment tool.* Vet J, 2011. **188**(3): p. 331-6.

25. Hughes, C.P., et al., *A new clinical scale for the staging of dementia.* Br J Psychiatry, 1982. **140**: p. 566-72.

26. Swan, G.E. and D. Carmelli, *Impaired olfaction predicts cognitive decline in nondemented older adults.* Neuroepidemiology, 2002. **21**(2): p. 58-67.

What is claimed is:

1. A composition comprising a compound of formula (I):



wherein

X is selected from CO, SO_2 and $(CH_2)_n$;

R_1 is selected from hydrogen, C_1-C_6 alkyl and C_1-C_6 alkanoyl;

R_2 is selected from hydrogen and C_1-C_6 alkyl;

R_3 is selected from hydrogen and a C_1-C_5 acetyl group; and

R_4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_5 alkoxy, and C_1-C_5 haloalkoxy;

n is an integer from 1 to 5, inclusive;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable excipient, e.g., suitable for oral administration.

2. The composition of claim 1, wherein the compound of formula (I) is selected from the group consisting of 2-hydroxy-5-phenethylamino-benzoic acid, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-[2-(3-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid, 5-[2-(4-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-difluoro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid, 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid, 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid, 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 5-[3-(3,4-dichloro-phenyl)-

propylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-(3-p-tolyl-propylamino)-benzoic acid, 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-benzylaminosalicylic acid, 5-(4-nitrobenzyl)aminosalicylic acid, 5-(4-chlorobenzyl)aminosalicylic acid, 5-(4-trifluoromethylbenzyl)aminosalicylic acid, 5-(4-fluorobenzyl)aminosalicylic acid, 5-(4-methoxybenzyl)aminosalicylic acid, 5-(2,3,4,5,6-pentafluorobenzyl)aminosalicylic acid, 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate, 5-(4-nitrobenzoyl)aminosalicylic acid, 5-(4-nitrobenzenesulfonyl)aminosalicylic acid, 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid, and 5-[3-(4-nitro-phenyl)-n-propyl]aminosalicylic acid.

3. The composition of claim 2, wherein the compound of formula (I) is 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid.

4. The composition of any one of claims 1-3, which comprises 1 mg to 1000 mg of the compound of formula (I) or its pharmaceutically acceptable salt.

5. The composition of any one of claims 1-4, which is a capsule comprising:
1 mg to 1000 mg of the compound of formula (I),
60% w/w lactose monohydrate,
5% w/w croscarmellose sodium,
0.5% w/w magnesium stearate, and
1% w/w sodium lauryl sulfate.

6. The composition of any one of claims 1-4, which is a food composition comprising:
1 mg to 1000 mg of the compound of formula (I),
42.7% w/w starch,
21.0% w/w crude protein,
14% w/w crude fat,
1.9% w/w crude fiber,

6.1% w/w crude ash,
1.4% w/w arginine,
0.75% w/w calcium,
1.1% w/w lysine,
1.18% w/w methionine plus cystine, and
0.5% w/w phosphorus.

7. The composition of any one of claims 1-4, which is a dietary supplement comprising:
1 mg to 1000 mg of the compound of formula (I),
12.0% w/w crude protein,
1.5% w/w crude fat,
0.4% w/w crude fiber,
1.5% w/w crude ash,
0.02% w/w calcium,
0.1% w/w potassium, and
78.0% w/w water.

8. The composition of any one of claims 1-4, which is a chewable tablet comprising:
1 mg to 1000 mg of the compound of formula (I),
3% w/w silicon dioxide,
0.05% w/w benzoic acid,
0.01% w/w sorbic acid,
5% w/w magnesium stearate,
20% w/w cellulose,
40% w/w chicken source,
3% w/w dry yeast, and
19% w/w glucose.

9. A use of the composition according to any one of claims 1 to 8 for manufacture of medicaments for treating cognitive dysfunction syndrome (CDS) through concurrent pharmacological inhibition of oxidative stress and inflammation.

10. A use of the compound according to any one of claims 1 to 8 for manufacture of medicaments for treating CDS through inhibiting of oxidative stress and prostaglandin E_2 synthesis.

11. A use of the compound according to any one of claims 1 to 8 for manufacture of medicaments for treating CDS through inhibiting of oxidative stress and microsomal prostaglandin E synthase-1.

12. A method of treating cognitive and/or neurobehavioral impairment, e.g., in neurological disease, comprising administering to a companion animal in need thereof a compound of formula (I):



wherein

X is selected from CO, SO_2 and $(CH_2)_n$;

R_1 is selected from hydrogen, C_1-C_6 alkyl and C_1-C_6 alkanoyl;

R_2 is selected from hydrogen and C_1-C_6 alkyl;

R_3 is selected from hydrogen and a C_1-C_5 acetyl group; and

R_4 is selected from a phenyl group, a phenoxy group, and a 5- to 10-membered aryl group which is unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_5 alkoxy, and C_1-C_5 haloalkoxy;

where n is an integer of 1 to 5, inclusive;

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, wherein the compound of formula (I) is selected from the group consisting of 2-hydroxy-5-phenethylamino-benzoic acid, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-[2-(3-trifluoromethyl-

phenyl)-ethylamino]-benzoic acid, 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid, 5-[2-(4-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-difluoro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid, 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid, 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid, 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 5-[3-(3,4-dichloro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-(3-p-tolyl-propylamino)-benzoic acid, 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-benzylaminosalicylic acid, 5-(4-nitrobenzyl)aminosalicylic acid, 5-(4-chlorobenzyl)aminosalicylic acid, 5-(4-trifluoromethylbenzyl)aminosalicylic acid, 5-(4-fluorobenzyl)aminosalicylic acid, 5-(4-methoxybenzyl)aminosalicylic acid, 5-(2,3,4,5,6-pentafluorobenzyl)aminosalicylic acid, 5-(4-nitrobenzyl)amino-2-hydroxy ethylbenzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxy ethylbenzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxy ethylbenzoate, 5-(4-nitrobenzoyl)aminosalicylic acid, 5-(4-nitrobenzenesulfonyl)aminosalicylic acid, 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid, and 5-[3-(4-nitro-phenyl)-n-propyl]aminosalicylic acid.

14. The method of claim 13, wherein the compound of formula (I) is 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid.

15. The method of claim 12, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered in a dose from 1 mg/kg of body weight to 200 mg/kg of body weight once a day.

16. The method of claim 12, comprising administering a composition, wherein the composition is a capsule comprising:

1 mg to 1000 mg of the compound of formula (I),

60% w/w lactose monohydrate,

5% w/w croscarmellose sodium,

0.5% w/w magnesium stearate, and

1% w/w sodium lauryl sulfate.

17. The method of claim 12, comprising administering a composition, wherein the composition is a food composition comprising:

1 mg to 1000 mg of the compound of formula (I),

42.7% w/w starch,

21.0% w/w crude protein,

14% w/w crude fat,

1.9% w/w crude fiber,

6.1% w/w crude ash,

1.4% w/w arginine,

0.75% w/w calcium,

1.1% w/w lysine,

1.18% w/w methionine plus cystine, and

0.5% w/w phosphorus.

18. The method of claim 12, comprising administering a composition, wherein the composition is a dietary supplement comprising:

1 mg to 1000 mg of the compound of formula (I),

12.0% w/w crude protein,

1.5% w/w crude fat,

0.4% w/w crude fiber,

1.5% w/w crude ash,

0.02% w/w calcium,
0.1% w/w potassium, and
78.0% w/w water.

19. The method of claim 12, comprising administering a composition, wherein the composition is a chewable tablet formula comprising:
1 mg to 1000 mg of the compound of formula (I),
3% w/w silicon dioxide,
0.05% w/w benzoic acid,
0.01% w/w sorbic acid,
5% w/w magnesium stearate,
20% w/w cellulose,
40% w/w chicken source,
3% w/w dry yeast, and
19% w/w glucose.

20. The method of any one of claim 12 to claim 19, wherein the cognitive and/or neurobehavioral impairment is selected from cognitive dysfunction syndrome, dysthymia, involutive depression, and confusional syndrome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2019/001409

A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/196(2006.01)i, A61K 9/00(2006.01)i, A61K 47/26(2006.01)i, A61K 47/38(2006.01)i, A61K 47/12(2006.01)i, A61K 47/20(2006.01)i, A61K 47/36(2006.01)i, A61K 47/42(2006.01)i, A61P 25/28(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K 31/196; A61K 31/136; A61K 31/192; A61K 31/216; A61K 31/42; A61K 33/00; A61P 25/24; C07C 103/46; C07D 233/56; C07D 401/12; A61K 9/00; A61K 47/26; A61K 47/38; A61K 47/12; A61K 47/20; A61K 47/36; A61K 47/42; A61P 25/28

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal), STN(Registry, Caplus), Google & keywords: 5-benylaminosalicylic acid, companion animal, neurodegenerative disorder, cognitive dysfunction syndrome, dysthymia, involutive depression

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 2394645 A2 (NEUROTECH PHARMACEUTICALS CO., LTD.) 14 December 2011 claim 1; paragraphs [0011], [0018], [0022]-[0025], [0028], [0033]	1-4,12-20
X	WO 2011-081445 A2 (NEUROTECH PHARMACEUTICALS CO., LTD.) 07 July 2011 claims 1-2 ; example 2	1-4
X	US 2007-0298129 A1 (GWAG, B. J. et al.) 27 December 2007 claims 1-16; paragraphs [0013], [0177]-[0192]	1-4,12-20
A	WO 94-13663 A1 (PFIZER INC.) 23 June 1994 the whole document	1-4,12-20
A	WO 86-03199 A1 (ITALFARMACO S.P.A.) 05 June 1986 the whole document	1-4,12-20

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents,such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
04 June 2020 (04.06.2020)	**04 June 2020 (04.06.2020)**

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea
Facsimile No. +82-42-481-8578

Authorized officer
HEO, Joo Hyung
Telephone No. +82-42-481-8150

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2019/001409

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 5-11
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required addtional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IB2019/001409

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 2394645 A2	14/12/2011	AU 2010-211491 A1	22/09/2011
		AU 2010-211491 B2	22/09/2016
		CA 2751638 A1	12/08/2010
		CA 2751638 C	05/07/2016
		CN 102316863 A	11/01/2012
		CN 102316863 B	16/09/2015
		DK 2394645 T3	12/01/2015
		EP 2394645 A4	17/10/2012
		EP 2394645 B1	08/10/2014
		ES 2527468 T3	26/01/2015
		JP 2012-517424 A	02/08/2012
		JP 5650134 B2	07/01/2015
		KR 10-1204108 B1	22/11/2012
		KR 10-2010-0091124 A	18/08/2010
		US 2012-0040939 A1	16/02/2012
		WO 2010-090494 A2	12/08/2010
		WO 2010-090494 A3	06/01/2011
WO 2011-081445 A2	07/07/2011	KR 10-1646701 B1	08/08/2016
		KR 10-2011-0075842 A	06/07/2011
		WO 2011-081445 A3	10/11/2011
US 2007-0298129 A1	27/12/2007	JP 2007-055999 A	08/03/2007
		JP 5208369 B2	12/06/2013
		US 2007-0049565 A1	01/03/2007
		US 2009-0149542 A1	11/06/2009
		US 2012-0301551 A1	29/11/2012
WO 94-13663 A1	23/06/1994	AT 194340 T	15/07/2000
		AU 5169693 A	04/07/1994
		CA 2150123 A1	23/06/1994
		CA 2150123 C	07/12/2004
		CN 1092771 A	28/09/1994
		DE 69328975 T2	09/11/2000
		DK 0675886 T3	18/09/2000
		EP 0675886 A1	11/10/1995
		EP 0675886 B1	05/07/2000
		EP 0806423 A1	12/11/1997
		ES 2147759 T3	01/10/2000
		FI 935529 A	09/12/1993
		GR 3034329 T3	29/12/2000
		JP 07-509490 A	19/10/1995
		JP 10-095780 A	14/04/1998
		JP 2722279 B2	04/03/1998
		JP 3165401 B2	14/05/2001
		MX 9307810 A	29/07/1994
		PT 675886 E	29/12/2000
		US 2001-0023248 A1	20/09/2001
		US 2003-0162766 A1	28/08/2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IB2019/001409

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 5854262 A	29/12/1998
		US 6369074 B1	09/04/2002
WO 86-03199 A1	05/06/1986	AU 5231186 A	18/06/1986
		CN 85109554 A	23/07/1986
		DK 346486 A	21/07/1986
		EP 0236329 A1	16/09/1987
		ES 8701717 A1	01/12/1986
		GR 852834 B	27/03/1986
		IT 1196348 B	16/11/1988
		JP 62-501703 A	09/07/1987
		KR 10-1987-0700608 A	30/12/1987
		PT 81566 A	01/12/1985
		PT 81566 B	07/04/1987
		ZA 8509035 B	27/08/1986